Zomedica director Johnny Powers buys $17.45k in company stock

  • Investing.com
Zomedica director Johnny Powers buys $17.45k in company stock

In a recent move, Johnny Powers, a director at Zomedica Corp. (NYSE:ZOM), has increased his stake in the company through the purchase of shares valued at a total of $17,450. The transactions took place on May 17, with the purchase price per share ranging between $0.17 and $0.179.

Powers' acquisition involved 100,000 shares of Zomedica's common stock, without par value, which is a significant vote of confidence in the pharmaceutical preparations company. Following these transactions, Powers now holds a total of 2,225,000 shares in Zomedica Corp.

Zomedica, based in Ann Arbor, Michigan, specializes in developing products for the health and well-being of companion animals. The company has been a topic of interest for investors in the life sciences and veterinary sectors.

Investors and market watchers often keep a close eye on insider transactions, such as those by Powers, as they can provide insights into the executives' perspectives on the company's future performance. The recent purchases by the Zomedica director may be interpreted as a positive signal about the company's prospects.

For shareholders and potential investors, the details of these transactions are available for review, reflecting the ongoing financial activities of company insiders and providing transparency into their investment decisions.

InvestingPro Insights

Following the recent insider share purchases by Johnny Powers, a director at Zomedica Corp. (NYSE:ZOM), the market is keen to understand the company's financial health and future potential. The InvestingPro platform offers a deeper dive into Zomedica's financial metrics and performance indicators that are pivotal for investors.

One of the key insights from InvestingPro is the company's financial position, with Zomedica holding more cash than debt on its balance sheet, which can be a sign of financial stability. This is particularly important for investors as it suggests the company has a buffer to fund operations and invest in growth opportunities. Additionally, Zomedica has been noted for its significant return over the last week, month, and three months, with price total returns of 35.42%, 41.44%, and 53.58% respectively. These figures indicate a robust short-term performance that might catch the eye of momentum investors.

On the data front, Zomedica's market capitalization stands at approximately $168.55 million USD. The company's revenue growth for the last twelve months as of Q1 2024 was 25.68%, which is a positive sign of its ability to increase sales. However, the operating income margin for the same period was -132.74%, reflecting the challenges the company faces in turning revenue into operating profit.

For those interested in further insights, there are additional InvestingPro Tips available on the platform, including the company's liquidity position and profitability metrics. With a total of 7 additional tips to explore, investors can gain a comprehensive understanding of Zomedica's financial health and potential investment value. To access these insights and more, investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or


Related Articles